Cargando…

PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome

Conjunctival melanoma (CM) iss a rare and aggressive tumour that is increasing in frequency. The prognostic value of PD-L1 expression, alone or in combination with CD8 and PD-1 expression and the BRAF and NRAS status, has not been determined in CM to date. We evaluated the expression of PD-L1, CD8,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lassalle, Sandra, Nahon-Esteve, Sacha, Frouin, Eric, Boulagnon-Rombi, Camille, Josselin, Nicolas, Cassoux, Nathalie, Barnhill, Raymond, Scheller, Boris, Baillif, Stéphanie, Hofman, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731195/
https://www.ncbi.nlm.nih.gov/pubmed/33266349
http://dx.doi.org/10.3390/ijms21239147
_version_ 1783621850336591872
author Lassalle, Sandra
Nahon-Esteve, Sacha
Frouin, Eric
Boulagnon-Rombi, Camille
Josselin, Nicolas
Cassoux, Nathalie
Barnhill, Raymond
Scheller, Boris
Baillif, Stéphanie
Hofman, Paul
author_facet Lassalle, Sandra
Nahon-Esteve, Sacha
Frouin, Eric
Boulagnon-Rombi, Camille
Josselin, Nicolas
Cassoux, Nathalie
Barnhill, Raymond
Scheller, Boris
Baillif, Stéphanie
Hofman, Paul
author_sort Lassalle, Sandra
collection PubMed
description Conjunctival melanoma (CM) iss a rare and aggressive tumour that is increasing in frequency. The prognostic value of PD-L1 expression, alone or in combination with CD8 and PD-1 expression and the BRAF and NRAS status, has not been determined in CM to date. We evaluated the expression of PD-L1, CD8, PD-1 in CM and investigated whether there was an association between the expression of these markers and the BRAF and NRAS molecular profile as well as some clinico-pathological criteria. A total of sixty-five CM were assessed for PD-L1, PD-1, and CD8 expression by immunohistochemistry (IHC) and for BRAF and NRAS genomic alterations using molecular biology techniques and anti-BRAF and anti-NRAS antibodies. PD-L1 expression in tumour cells (TC) was very low or absent but detected in tumour-infiltrating immune cells (IC). A correlation was observed between the expression of PD-L1, CD8, and PD-1 in IC. No correlation between PD-L1 expression (in tumour and/or immune cells) and BRAF or NRAS mutations was observed. PD-L1 expression in IC correlated with a higher pTNM stage and PD-L1 expression in TC with worse disease-specific survival. PD-L1 expression is a potential prognostic biomarker that correlates with poor prognosis in CM patients.
format Online
Article
Text
id pubmed-7731195
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77311952020-12-12 PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome Lassalle, Sandra Nahon-Esteve, Sacha Frouin, Eric Boulagnon-Rombi, Camille Josselin, Nicolas Cassoux, Nathalie Barnhill, Raymond Scheller, Boris Baillif, Stéphanie Hofman, Paul Int J Mol Sci Article Conjunctival melanoma (CM) iss a rare and aggressive tumour that is increasing in frequency. The prognostic value of PD-L1 expression, alone or in combination with CD8 and PD-1 expression and the BRAF and NRAS status, has not been determined in CM to date. We evaluated the expression of PD-L1, CD8, PD-1 in CM and investigated whether there was an association between the expression of these markers and the BRAF and NRAS molecular profile as well as some clinico-pathological criteria. A total of sixty-five CM were assessed for PD-L1, PD-1, and CD8 expression by immunohistochemistry (IHC) and for BRAF and NRAS genomic alterations using molecular biology techniques and anti-BRAF and anti-NRAS antibodies. PD-L1 expression in tumour cells (TC) was very low or absent but detected in tumour-infiltrating immune cells (IC). A correlation was observed between the expression of PD-L1, CD8, and PD-1 in IC. No correlation between PD-L1 expression (in tumour and/or immune cells) and BRAF or NRAS mutations was observed. PD-L1 expression in IC correlated with a higher pTNM stage and PD-L1 expression in TC with worse disease-specific survival. PD-L1 expression is a potential prognostic biomarker that correlates with poor prognosis in CM patients. MDPI 2020-11-30 /pmc/articles/PMC7731195/ /pubmed/33266349 http://dx.doi.org/10.3390/ijms21239147 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lassalle, Sandra
Nahon-Esteve, Sacha
Frouin, Eric
Boulagnon-Rombi, Camille
Josselin, Nicolas
Cassoux, Nathalie
Barnhill, Raymond
Scheller, Boris
Baillif, Stéphanie
Hofman, Paul
PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome
title PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome
title_full PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome
title_fullStr PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome
title_full_unstemmed PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome
title_short PD-L1 Expression in 65 Conjunctival Melanomas and Its Association with Clinical Outcome
title_sort pd-l1 expression in 65 conjunctival melanomas and its association with clinical outcome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7731195/
https://www.ncbi.nlm.nih.gov/pubmed/33266349
http://dx.doi.org/10.3390/ijms21239147
work_keys_str_mv AT lassallesandra pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome
AT nahonestevesacha pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome
AT frouineric pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome
AT boulagnonrombicamille pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome
AT josselinnicolas pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome
AT cassouxnathalie pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome
AT barnhillraymond pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome
AT schellerboris pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome
AT baillifstephanie pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome
AT hofmanpaul pdl1expressionin65conjunctivalmelanomasanditsassociationwithclinicaloutcome